Immunotherapy Combination for Metastatic Uveal Melanoma
Posted: Wednesday, November 28, 2018
The phase II GEM1402 trial, conducted by Josep Maria Piulats Rodriguez, PhD, of IDIBELL Bellvitge Biomedical Research Institute, Barcelona, and colleagues, indicated that nivolumab plus ipilimumab may prove to be a feasible option for patients with metastatic uveal melanoma in terms of efficacy and toxicity. These findings were presented at the 2018 European Society for Medical Oncology (ESMO) Congress (Abstract 1247PD) in Munich.
For this single-arm trial led by the Spanish Melanoma Group, the investigators enrolled 50 untreated patients with metastatic uveal melanoma. They all had an Eastern Cooperative Oncology Group status of 0 or 1. The patients were given nivolumab plus ipilimumab during four inductions, followed by nivolumab until progressive disease, toxicity, or patient withdrawal. A total of 33 patients completed 2 cycles, and 7 patients stopped after 1 dose.
Treatment-related adverse events were reported in 46 patients, and treatment was discontinued in 9 patients. Grade ≥ 3 side effects were reported in about half of the treated patients, and all such events were resolved by following related guidelines. The overall response rate was 12%, disease stabilization was 52%, and the disease control rate was 64%. With a median follow-up of 7.06 months, progression-free survival was 3.27 months, and the median overall survival was 12.7 months.